Analysts expect Rallybio Corp to report revenue of 95,900.50 for Q4 25, against a range of 86,980.41 to 104,820.59. The most recent reported quarter, Q3 25, came in at 212,000.00, a 239.3% beat against the 62,489.46 consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 212,000.00 | 212,000.00 | - | - | - | - | - | - | - | - | |||||||||||||
| High Estimate | 0.00 | 64,545.68 | 104,820.59 | 0.00 | 0.00 | 0.00 | 0.00 | 21.16 M | 21.77 M | 25.17 M | |||||||||||||
| Low Estimate | 0.00 | 60,433.24 | 86,980.41 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00 M | 19.49 M | 20.78 M | |||||||||||||
| Consensus Estimate | 0.00 | 62,489.46 | 95,900.50 | 0.00 | 0.00 | 0.00 | 0.00 | 20.08 M | 20.63 M | 22.97 M |
Analysts expect Rallybio Corp to report earnings per share of -1.16 for Q4 25, against a range of -1.26 to -1.06. The most recent reported quarter, Q3 25, came in at 2.88, a 260.9% beat against the -1.79 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.08 | -2.00 | -1.68 | -1.76 | 2.88 | - | - | - | - | - | - | - | - | |||||||||||||
| High Estimate | -2.60 | -2.14 | -2.03 | -1.73 | -1.66 | -1.06 | -1.20 | -1.17 | -1.27 | -1.56 | -2.44 | -2.88 | -2.30 | |||||||||||||
| Low Estimate | -2.80 | -2.58 | -2.41 | -2.01 | -1.92 | -1.26 | -1.32 | -1.25 | -1.49 | -1.76 | -2.74 | -3.34 | -2.46 | |||||||||||||
| Consensus Estimate | -2.70 | -2.36 | -2.22 | -1.87 | -1.79 | -1.16 | -1.26 | -1.21 | -1.38 | -1.66 | -2.59 | -3.11 | -2.38 |